Head and Neck Diseases by Alexandros G.Sfakianakis: Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.

Τετάρτη 4 Ιανουαρίου 2017

Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.

http:--highwire.stanford.edu-icons-exter

https:--http://ift.tt/2bsbOVj

Related Articles

Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.

Haematologica. 2016 Mar;101(3):e111-5

Authors: de Rooij MF, Kuil A, Kraan W, Kersten MJ, Treon SP, Pals ST, Spaargaren M

PMID: 26635033 [PubMed - indexed for MEDLINE]

http://ift.tt/2izB7MJ

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Εγγραφή σε: Σχόλια ανάρτησης (Atom)